Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

First International Summit on Interventional Pharmacoeconomics

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Mar

Today In Oncology

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Related Videos

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Deborah Collyar: What's In It for Patients?

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

The Interventional Pharmacoeconomic Toolbox Panel Discussion

AI As Collaborator in Cancer Research and in Clinical Care

AI Use in Cancer Diagnosis, Prognosis, and Treatment: Are We There Yet?

Neoadjuvant GOLP in High-Risk Intrahepatic Cholangiocarcinoma

Gedatolisib-Based Regimens in HR-Positive HER2-Negative PIK3CA Wild-Type Advanced Breast Cancer

Hyperplasia and the Link Between Obesity and Cancer